GH Research PLC (NASDAQ:GHRS) Given Average Rating of “Moderate Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $29.75.

A number of brokerages have weighed in on GHRS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research note on Wednesday, October 8th. Needham & Company LLC started coverage on GH Research in a research note on Monday, October 13th. They set a “buy” rating and a $19.00 price objective for the company. HC Wainwright cut their target price on GH Research from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday. Zacks Research downgraded GH Research from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a research report on Saturday.

Institutional Investors Weigh In On GH Research

Institutional investors and hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. raised its holdings in GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of GH Research in the 2nd quarter worth $79,000. Virtus Investment Advisers LLC bought a new stake in shares of GH Research in the 2nd quarter worth $89,000. XTX Topco Ltd purchased a new position in shares of GH Research in the first quarter worth $169,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Trading Up 5.0%

Shares of GH Research stock opened at $14.22 on Wednesday. GH Research has a 12 month low of $6.72 and a 12 month high of $20.50. The firm has a market capitalization of $739.87 million, a P/E ratio of -19.22 and a beta of 0.97. The business has a fifty day simple moving average of $13.46 and a two-hundred day simple moving average of $13.11.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). Analysts predict that GH Research will post -0.8 earnings per share for the current year.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).